Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Bardees M Foda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Drug Resistance, Neoplasm, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, MSU College of Human Medicine Gran Fondo Fundraiser.
Abstract (Originalsprache)
Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune therapies limits the benefits of current treatments. Identifying and adding anti‐resistance agents to current treatment protocols can potentially improve clinical responses. Myocardin‐related transcription factor (MRTF) is a transcriptional coactivator whose activity is indirectly regulated by actin and the Rho family of GTPases. We previously demonstrated that development of BRAF inhibitor (BRAFi) resistance frequently activates the Rho/MRTF pathway in human and mouse BRAF V600E melanomas. In clinical trials, pretreatment with BRAFi reduces the benefit of immune therapies. We aimed to test the efficacy of concurrent treatment with our MRTF pathway inhibitor CCG‐257081 and anti‐PD1 in vivo and to examine its effects on the melanoma immune microenvironment. Because MRTF pathway activation upregulates the expression of immune checkpoint inhibitor genes/proteins, we asked whether CCG‐257081 can improve the response to immune checkpoint blockade. CCG‐257081 reduced the expression of PDL1 in BRAFi‐resistant melanoma cells and decreased surface PDL1 levels on both BRAFi‐sensitive and ‐resistant melanoma cells. Using our recently described murine vemurafenib‐resistant melanoma model, we found that CCG‐257081, in combination with anti‐PD1 immune therapy, reduced tumor growth and increased survival. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8 + T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophages. Here, we propose CCG‐257081 as an anti‐resistance and immune therapy‐enhancing anti‐melanoma agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA.
- Molecular Genetics and Enzymology Department, National Research Centre, Dokki, Egypt.
- Department of Physiology, Michigan State University, East Lansing, Michigan, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Nicholas V. Perricone, M.D. Division of Dermatology, Department of Medicine, Michigan State University, East Lansing, Michigan, USA.
ORCID-Profile: Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Förderung
- NCI NIH HHS
- MSU College of Human Medicine Gran Fondo Fundraiser
Zitieren
APA
Foda, B. M., Misek, S. A., Gallo, K. A., & Neubig, R. R. (2024). Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade. International Journal of Cancer. https://doi.org/10.1002/ijc.35056
Vancouver
Foda BM, Misek SA, Gallo KA, Neubig RR. Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade. International Journal of Cancer. 2024. doi:10.1002/ijc.35056
BibTeX
@article{Foda2024,
author = {Foda, Bardees M and Misek, Sean A and Gallo, Kathleen A and Neubig, Richard R},
title = {Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35056}
}
EUVIMED